Pheromone Sciences Corp. (PHS) - 500 Beiträge pro Seite

[URANI]

Habe mal auf www.canadianinsider.com ein bissel geschaut und an erster Stelle der Insiderkäufe steht PHEROMONE SCIENCES! Es sind im Juni ordentlich Stücke von einen gewissen Herrn Randhawa, Devinder gekauft wurden! Da ich mich überhaupt nicht mit Biotiteln auskenne wollte ich mal eure Meinung zu PHEROMONE SCIENCES wissen.

www.pheromonesciences.com
WKN: A0BLZ1
Symbol: PSH
ISIN: CA71742P1080

Finanzberichte,Direktoren usw. stehen auf der HP

Vielen Dank
URANI

Pheromone Sciences Corp. (PHS) As of July 5th, 2006
Filing Date Transaction Date Insider Name Nature of transaction Securities # or value acquired or disposed of Unit Price

Jun 28/06 Jun 23/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 4,000 $0.330
Jun 26/06 Jun 22/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 40,000 $0.350
Jun 26/06 Jun 22/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 20,000 $0.350
Jun 22/06 Jun 20/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 25,000 $0.330
Jun 22/06 Jun 20/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 25,000 $0.350
Jun 22/06 Jun 13/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 100,000 $0.365
Jun 19/06 Jun 14/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 1,000 $0.330
Jun 19/06 Jun 14/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 100,000 $0.340
Jun 19/06 Jun 09/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 7,500 $0.370
Jun 15/06 Jun 08/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 20,000 $0.370

Hier noch ein paar Informationen von der Homepage


Pheromone Sciences Corp. (PHS) ist eine Biotechnologieforschung und -Verwertungsgesellschaft, die auf Kommerzialisierung der erfinderischen medizinischen Technologien gerichtet wird. Sein Leitung Projekt ist Forschung in das Aufheben von Diabetes des Typs 1 (Insulinabhängiger) durch verpflanzte Schweinkleine insel und Sertoli Zellen. Die Inselzellen produzieren Insulin, das mit menschlichen Körpern kompatibel ist, während die Sertoli Zellen die Inselzellen vor Angriff durch das immune System der Person schützen. Pheromon hat das ausschließliche Recht zu den Patenten und dazugehöriges geistiges Eigentum für den therapeutischen Gebrauch von Sertoli Zellen in den Vereinigten Staaten, in Kanada und in den meisten industrialisierten Hauptnationen.

Forschungsprojekte

Gegenwärtiges Forschung Projekt

Die Firma schifft sich auf neuer ein, und möglicherweise groundbreaking Forschung in die Behandlung von Typ 1diabetes mit verpflanzten Schweinzellen - und ohne die Notwendigkeit an den Patienten so tuend, alle mögliche Anti-ablehnung Drogen zu benutzen. Die Firma beabsichtigt, das Resultat in den Handel zu bringen, indem sie Genehmigung durch die zuständige Aufsichtsbehörde für das Verfahren während der industrialisierten Welt erreicht. Unter den Bezeichnungen der vor kurzem abgeschlossenen Joint Venture Vereinbarung, besitzt Pheromon jetzt die exklusiven weltweiten Rechte für den Gebrauch von therapeutischem Gebrauch von Sertoli Zellen, das Schlüsselc$anti-ablehnung Mittel, das die Technologie ermöglicht.

Die Technologie basiert auf den Zelle Vorbereitung und Transplantverfahren von Dr. Rafael Valdes, der bereits diese Technologie für das Behandeln der Menschen in Mexiko verwendet. Dr. Valdes hat die Resultate seiner ersten klinischen Spuren in der September 2005 Ausgabe des europäischen Journals von Endokrinologie veröffentlicht, aber sein Verfahren ist nicht für irgendwelche Länder anders als Mexiko anerkannt. Pheromon beabsichtigt, rigoroses wissenschaftliches Experimentieren zu folglich zu leiten produzieren die Qualität der Wissenschaft notwendig, Genehmigung durch die zuständige Aufsichtsbehörde zu erreichen sein Gebrauch in den Hauptmärkten healthcare alle Welt.


Letzte Meldung:

Montag 26. Jun. 2006
Justin Leushner ernannt zur Direktion

--------------------------------------------------------------------------------

Kelowna, B.C. -- Um den Fortschritt seines Diabetesproduktentwicklung Projektes zu erleichtern, freut sich Pheromone Sciences Corp. („Pheromon“) diesen Herrn Justin Leushner von London, Ontario zu verkünden, ist genannt worden den Präsidenten der Firma, wirkungsvoll sofort. Zusätzlich ist Herr Leushner zur Direktion ernannt worden. Er ist z.Z. der Manager des kleine Inseltransplant-Programms am der London Gesundheit Wissenschaften Transplant-Programm Multi-Organ Welt Mitte („LHSC“) berühmten. Seine Rolle als Präsident schließt Primärverantwortlichkeit für die überwachung des Fortschritts des Diabetes-Forschung Projektes des Pheromons ein, das am Service des LHSCS geleitet wird. Das Projekt ist Primärfokus forschung des Pheromons und wird von der Firma finanziert, die vor kurzem $3.2 Million finanzierend durchgeführt wird.

„Herr Leushner holt mit ihm ein vollständiges Wissen der Forschung Ziele und Möglichkeiten der Technologie, die wir uns entwickeln werden,“ sagte Pheromon-Generaldirektor-Entwickler Randhawa. „Seine Balance des Geschäft Scharfsinnes und des Wissenschaftsverständnisses bildet ihn einen ausgezeichneten Repräsentanten von unserem Profil der Firma.“

Herr Leushner ist auch Präsident und der 50-Prozent-Aktionär in Sertonex Inc., ein privates London Ontario gegründete Firma Pheromon erwirbt in den Stadien resultierend aus Pheromon seine Option unter einer neuen Joint Venture ausübend und Vereinbarung mit Sertonex und Sertoli Technologies Inc. von Tucson, Arizona finanzierend. Unter den Bezeichnungen dieser Vereinbarung, Sertonex und Sertoli haben Technologien beide das Recht, ein Mitglied zum Brett des Pheromons zu ernennen.

Über Justin Leushner
Herr Leushner hat eine umfangreiche und verschiedene Geschäft Karriere in den Lebenwissenschaften und in den Biotechnologieindustrien gehabt. Er hat an vielen unternehmerischen Start-upfirmen teilgenommen, die Verbraucherprodukte, neue Technologien und Biotechnologie eingeschlossen haben. Er war auch für das Entwickeln eines nationalen molekularen Diagnose Programms für MDS Inc., Kanadas größte Firma der Lebenwissenschaft verantwortlich, und gedient als Geschäft Analytiker- und Mappenberater zur kanadischen medizinischen Entdeckung-Kapital. 2004 Co-gründete Herr Leushner Sertonex Inc. mit Dr. David White, jetzt Primärforscher des Pheromons auf dem Diabetesprojekt.

Ein MBA Absolvent der Universität der Schule Ivey Westontarios des Geschäfts, Herr Leushner hält auch ein B.Sc in der Zelle Physiologie/in den Genetik von der Universität von Britisch-Kolumbien und in den zahlreichen technischen Kennzeichnungen in der gerichtlichen Wissenschaft und in der molekularen Biologie.

Über das Forschung Projekt
Projekt Forschung des Pheromons soll zu ein Verfahren führen, das durch die USnahrungsmittel-und Droge-Leitung für das Behandeln von Diabetes genehmigt wird, indem man in Menschen eine Vorrichtung verpflanzt, die Schweinkleine inseln und Sertoli Zellen enthält. Die Inselzellen produzieren das Insulin, das zu dem fast identisch ist, das in den Menschen gefunden wird, und die Sertoli Zellen schützen natürlich die Inselzellen vor Angriff durch das immune System des Körpers. Die Forschung basiert auf einigen Beweis-vonkonzept Experimenten, die vom Dr. White und andere durchgeführt werden.

Pheromone Sciences Corp. ist eine Biotechnologieforschung und -Verwertungsgesellschaft, die auf die Kommerzialisierung der medizinischen Technologien gerichtet wird.



IM NAMEN DES BRETTES

„Entwickler Randhawa“

Entwickler Randhawa, Präsident


Für weitere Informationen Kontakt:

Telefon: [phone] Herr Phil Morehouse
TELEFAX: [phone] Pheromone Sciences Corp.

Telefon: [phone] Herr Justin Leushner
TELEFAX: [phone] Sertonex Inc.

Telefon: [phone] Ms Jan. McCoy Hutchinson
TELEFAX: [phone] Sertoli Technologies Inc.

[URANI]

Hauptbüro: Pheromone Sciences Corp.
Web site: http://www.pheromonesciences.com/
Email: [e-mail]
Adresse: #810 - Delphin-Allee 1708
Kelowna, Britisch-Kolumbien
Kanada V1Y 9S4
Telefon: [phone]
Telefax: 250-868-8493
Tollfree: 888-318-7062



Forschung Projekt: Justin Leushner
Sertonex Inc.
Email: [e-mail]
Telefon: [phone]
Telefax: [phone]



Geschäftliche Entwicklung: Phil Morehouse
Pheromone Sciences Corp.
Email: [e-mail]
Adresse: #810 - Delphin-Allee 1708.
Kelowna, Britisch-Kolumbien
Kanada V1Y 9S4
Telefon: [phone]
Telefax: 250-868-8493
Tollfree: 1-888-318-7062

[URANI]

Tatsache Blatt

TSX Wagnissymbol: PHS

Finanzverhältnisse
Ausgegebene Aktien: 38.7 Million
Völlig verdünnt: 45.2 Million
Arbeitskapital: $3.2 Million
Völlig verdünnt: $6.6 Million
52 Woche Hi/Low: $0.71-$0.11

Investition-Höhepunkte

·Am 23. Mai 2006 Pheromon-Wissenschaften führten $3.2 Million, non-brokered Privatplazierung für 8 Million Maßeinheiten bei $0.40 pro Maßeinheit durch. Jede Maßeinheit besteht einem allgemeinen Anteil und aus Halb eine Erwerb Ermächtigung, die für zwei Jahre bei $0.60 exercisable ist.
· Am 23. Mai 2006 die Firma empfangene TSX Zustimmung, damit eine Joint Venture und eine Bezugsrechtsvereinbarung Sertonex Inc., eine private London Ontario medizinische Forschung Firma sich engagierte in der wissenschaftlichen Forschung finanziert und erwirbt, die an der überwindung von Transplantablehnung verwiesen wird. Als Teil des Wagnisses erwirbt Pheromongleichlaufendes von Sertoli Technologies Inc. von Tucson Arizona die exklusiven weltweiten Rechte zu allen seinen Patenten und zu anderem geistigem Eigentum, die auf dem therapeutischen Gebrauch von Sertoli Zellen bezogen werden.
· Pheromon verkündet ein Absichtsschreiben, um ein Interesse an Sertonex Inc., eine private London Ontario gegründete Firma zu finanzieren und zu erwerben, die an der wissenschaftlichen Forschung teilnimmt, die an der überwindung von Transplantablehnung verwiesen wird. Als Teil des Abkommens unterzeichnet PSC eine Lizenzvereinbarung mit Sertoli Technologies Inc. von Tuscon Arizona, Rechte zu seinem geistigen Eigentum zu erwerben.
· Pheromon-Wissenschaften schließt den WertKaufvertrag mit HealthWatchSystems, Inc., für alles propoerty, das mit der Ergiebigkeit-Monitortechnologie am 31. August 2004 für eine Gesamtbetrachtung von C$500,000 verbunden ist. und eine abgestufte Abgabe auf weltweiten Verkäufen.
· FDA-Zustimmung empfing 25. September 2002 für PSC Ergiebigkeit-Monitor.

Positionen

Hauptbüro/FORSCHUNG UND Geschäftsoperationen:
#810 - Delphin-Allee 1708., Kelowna BC V1Y 9S4
Telefon: [phone] Telefax: 250.868.8493

Management

Das Management von Pheromone Sciences Corp. hat eine Fülle der Erfahrung in der ausgedehnten Gesundheitspflegeindustrie sowie in Unternehmensleitung und in der Entwicklung. Die Mannschaft hat vielen neue Gesundheit - in Verbindung stehende Produkte zum Markt geholt und hat erfolgreich ihre Managementfähigkeiten über ihren Karrieren demonstriert.

William A. Cochrane, OC, MD FRCP (c) - Vorsitzender
Gründendekan von Medizin, Universität von Calgary
Präsident Emeritus, Universität von Calgary
Vice-Chancellor Emeritus, Universität von Calgary
Hinter Vorsitzendem nationale Biotechnologie-Gutachterkommission
Ehemaliger Abgeordneter Minister des Gesundheitswesens, Gov't von Alberta
Ehemaliger Vorsitzender u. CEO, Connaught Labors Ltd.

Devinder Randhawa, M.B.A. - Präsident u. CEO
Präsident, RD Capital Inc.
Founder und CEO, Strathmore Minerals Corp.
Vorsitzender und CEO von Pacific Asia Canada Energy Inc.
Präsident, Lariat Capital Inc., das mit Medicure im November 1999 vermischte
Gründer und ehemaliger Präsident, Royal County Minerals Corp.
Versenken, RaubCapital Inc., die Rauberforschung wurde.

Patrick Groening, C.A., C.P.A. - CFO
Herr Groening erreichte seine Wirtschaftsprüferkennzeichnung 1999 und ist ein Mitglied des Instituts der Wirtschaftsprüfer von Britisch-Kolumbien. Er auch hält eine professionelle Buchhaltungkennzeichnung als Wirtschaftsprüfer und ist Mitglied des Illinois Brettes der Prüfer in den Vereinigten Staaten. Zusätzlich zum Sein ein Revisor für einige Jahre, Herr Groening hat das beratende Geschäft, Informationstechnologie und Finanzbuchhaltungdienstleistungen zu vielen mittleren und großen Organisationen zur Verfügung gestellt.

William Milligan, B.Sc. - Direktor
Hauptgeschäft Offizier, Micrologix Ltd.
Ehemaliger Präsident und CEO Cytran Inc.
Former C.E.O., Intellivax International Inc.
Ehemaliger Vizepräsident, geschäftliche Entwicklung -
Biomedizinische Abteilung Hoffman La Roche

Christopher Neuman, B.Sc., B.Comm., MBA - Direktor
Ehemaliges Generaldirektor, ALZA Kanada
Former President/GM, Baker Cummins Inc.
Ehemaliger Direktor des Marketings u. der geschäftliche Entwicklung, Aufladungen Pharma
Ehemaliger Direktor von Marketing, Marion Merrell Dow Inc.

Andrew Saxton - Direktor
Chairman, Investment Committee, Insurance Corporation von B.C.
Direktor, VSM MEDTech Ltd.
Mitglied, Beratungsstelle, B.C. Leben-Wissenschaften Kapital

Eldon Smith MD, Direktor
Professor der Medizin-Universität von Calgary; Ehemaliger Dekan der Fähigkeit von Medizin; Ehemaliger Präsident der Verbindung der kanadischen medizinischen Hochschulen; Vasogen und BioMax von den Technologien verweisen.

[URANI]

Re: News Release - Wednesday, July 19, 2006
Pheromone Builds Scientific Advisory Board: Appoints Dr. Norman
Wong to Help Develop Diabetes Product
=======================================================================

***********************************************************************
***********************************************************************
PLEASE NOTE: a configuration error in our data base may have
inadvertently omitted your email address from previous News Release
announcements. Please check our web site for a complete list of current
releases: http://www.pheromonesciences.com/s/NewsReleases.asp" target="_blank" rel="nofollow ugc noopener">http://www.pheromonesciences.com/s/NewsReleases.asp

We apologize for any inconvenience.
***********************************************************************
***********************************************************************

Kelowna, B.C. - Pheromone Sciences Corp. ("Pheromone") is pleased to
announce that Dr. Norman Wong, M.D., F.R.C.P.(C), has joined its
Scientific Advisory Board ("SAB") to assist the company with its
diabetes product development.

"With extensive experience in researching and treating diabetes
mellitus, Dr. Wong is an important addition to our Scientific Advisory
Board," stated Dr. David White, Chair of Pheromone's SAB. "His medical
career has demonstrated both his commitment to the treatment of
diabetes and his ability to commercialize research findings."

Dr. Wong is the co-founder of Resverlogix Corp. (TSX: RVX) and serves
as the Chairman of its SAB. He is also the Director of the Libin Gene
Therapy Unit and is a Professor in both the departments of Medicine and
Biochemistry & Molecular Biology at the University of Calgary.

About Dr. Wong
Dr. Wong graduated from the University of Calgary, Faculty of Medicine
in 1980, completed his internal medicine residency in 1983, and then
received his fellowship training in endocrinology at the University of
Minnesota. His research interest deals primarily with the molecular
actions of hormones and specifically that related to the regulation of
lipoprotein expression and pathogenesis of diabetes mellitus. He has
published numerous articles in the field of diabetes research. His
clinical interest encompasses patients with diabetes mellitus or
thyroid disease. In addition to his current positions, he has
previously held posts at the University of Calgary. as Associate
Vice-President of Research and International, and Assistant Dean
(Research) Faculty of Medicine.

About the Diabetes Research Project
Pheromone has recently completed a $3.2 million private placement to
fund its research into an innovative treatment for Type 1 (insulin
dependent) diabetes. Currently approved transplant procedures for
reversing diabetes are rarely used because of the lack of suitable
human organ donors and the need for patients to use immune suppressing
anti-rejection drugs for the rest of their lives. Pheromone is in the
process of developing a procedure to overcome these limitations by
inserting into an implantable device two types of pig cells: islet
cells that produce insulin compatible with humans, and Sertoli cells
which will naturally protect the islet cells from attack by the body's
immune system.

Using rigorous and widely accepted scientific experimentation methods,
Pheromone's goal is to receive approval for this cellular therapy
product from the United States Food and Drug Administration, and from
other national regulatory bodies throughout the world. The research is
based on several proof-of-concept studies completed by Dr. David White,
Pheromone's principal researcher, and others. The Company owns the
exclusive rights to over 20 patents related to the therapeutic use of
Sertoli cells.


Pheromone Sciences Corp. is a biotechnology research and development
company focused on commercializing medical technologies.


ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO


For further information contact:

Mr. Phil Morehouse
Pheromone Sciences Corp.
TEL: [phone]
FAX: [phone]

=======================================================================
Copyright (c) 2006 PHEROMONE SCIENCES CORP. (PHS) All rights reserved.
For more information visit our website at
http://www.pheromonesciences.com/ or send
mailto:[e-mail]
Message sent on Wed Jul 19, 2006 at 10:42:56 AM Pacific Time
=======================================================================

[URANI]

Thank you for your interest in Pheromone Sciences. At your request you have been added to our email list. Company news releases and investor information updates will be sent to you periodically as they become available. Currently investor packages are being updated and are not yet ready for distribution, but will be forwarded to you via email when completed. Attached is the current Fact Sheet.







Regards,







Phil Morehouse



Pheromone Sciences Corp.




#810 – 1708 Dolphin Ave.


Kelowna, BC V1Y 9S4



Canada



Ph: 250-868-8177



Fax: [phone]



TF: 888-882-8177



[e-mail]

[URANI]

UND ES WIRD WEITER FLEIßIG GEKAUFT............




Pheromone Sciences Corp. (PHS) As of July 23rd, 2006
Filing Date Transaction Date Insider Name Nature of transaction Securities # or value acquired or disposed of Unit Price

Jul 19/06 Jul 14/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 33,000 $0.330

Jul 19/06 Jul 18/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 83,000 $0.335

Jul 19/06 Jul 18/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 50,000 $0.340

Jul 17/06 Jul 13/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 153,500 $0.330

Jul 17/06 Jul 11/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 16,000 $0.330

Jul 13/06 Apr 15/06 Milligan, William Doran 50 - Grant of options Options 95,000 $40.000

Jul 13/06 Apr 15/06 Milligan, William Doran 38 - Redemption, retraction, cancellation, repurchase Options -30,000

Jul 10/06 Jul 06/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 65,000 $0.340

Jul 10/06 Jul 06/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 113,500 $0.330

Jul 06/06 Jul 06/06 Randhawa, Devinder 99 - Correction of information Options 150,000

[URANI]

Pheromone's White serves up research results

2006-07-25 10:03 ET - News Release

Mr. Dev Randhawa reports

PHEROMONE'S PRINCIPAL RESEARCHER TO PRESENT 'DIABETES REVERSAL MODEL' AT WORLD TRANSPLANT CONGRESS

Pheromone Sciences Corp. has confirmed that Dr. David White, principal researcher on the company's Diabetes Reversal product development, will present his latest research results at the World Transplant Congress in Boston on Friday, July 28.

In a special session convened by the International Xenotransplant Association, Dr. White will unveil the experimental model (pig to rat) in which he demonstrated enhanced suppression of the host's immune system to allow for long-term survival of implanted, insulin-producing islet cells.

Dr. White's model is the basis for Pheromone's research project on reversing diabetes by co-transplanting two types of pig cells in an implanted device: (a) islet cells, which produce insulin compatible for humans; and (b) Sertoli cells, which will naturally protect those injected islet cells from attack by the body's immune defence system. Pheromone owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

By using rigorous and widely accepted scientific experimentation methods, Pheromone's goal is to receive approval for this cellular therapy product from the United States Food and Drug Administration, and from other national regulatory bodies throughout the world.

[URANI]

Pheromone builds advisory board for diabetes product


2006-07-28 09:39 ET - News Release

Mr. Dev Randhawa reports

PHEROMONE SCIENCES CORP.: BUSINESS ADVISORY BOARD ESTABLISHED TO COMMERCIALIZE DIABETES PRODUCT

Pheromone Sciences Corp. has established a business advisory board to strategically guide the directors and management in commercializing the company's diabetes product. Pheromone has appointed three former company directors to the board: William Milligan, Andrew Saxton and Christopher Neuman.

"These men all have an intimate understanding of the company and the business of biotechnology," said Dr. William Cochrane, chairman of the board of directors. "We are glad Pheromone will continue to get the benefit of their expertise and wisdom."

About William Milligan

Since 2002, Mr. Milligan has served as the chief business officer of Migenix Inc., a biopharmaceutical company focused on innovative drugs for life-threatening diseases. He has extensive experience in leading and managing pharmaceutical commercialization, financing, product development, licensing and partnerships from both large pharmaceutical and small biotechnology companies. Mr. Milligan was previously president and chief executive officer of Cytran Inc., a private biotechnology company based in Seattle, and chief executive officer of Intellivax International Inc., a private biotechnology company based in Montreal and Baltimore. Prior to that he worked for Hoffmann-La Roche Ltd. (Canada) and Eli Lilly Inc. (Canada). At Roche, he held vice-president positions in pharmaceuticals, including: business development and new product planning, sales division, and biomedical division. Mr. Milligan served as a director of Pheromone from 2000 to 2006.

[URANI]

Business Advisory Board Established to Commercialize Diabetes
Product
=======================================================================

Kelowna, B.C. -- Pheromone Sciences Corp. ("Pheromone") is pleased to
announce that it has established a Business Advisory Board to
strategically guide the directors and management in commercializing the
Company's diabetes product. Pheromone has appointed three former
Company directors to the board: William Milligan, Andrew Saxton and
Christopher Neuman.

"These men all have an intimate understanding of the Company and the
business of biotechnology," said Dr. William Cochrane, Chairman of the
Board of Directors. "We are glad Pheromone will continue to get the
benefit of their expertise and wisdom."

About William Milligan
Since 2002 Mr. Milligan has served as the Chief Business Officer of
Migenix Inc. (TSX: MGI), a biopharmaceutical company focused on
innovative drugs for life-threatening diseases. He has extensive
experience in leading and managing pharmaceutical commercialization,
financing, product development, licensing and strategic alliances from
both large pharmaceutical and small biotechnology companies. Mr.
Milligan was previously President & CEO of Cytran Inc., a private
biotechnology company based in Seattle, and CEO of Intellivax
International Inc., a private biotechnology company based in Montreal
and Baltimore. Prior to that he worked for Hoffmann-La Roche Ltd.
(Canada) and Eli Lilly Inc. (Canada). At Roche, he held Vice President
positions in Pharmaceuticals including: Business Development and New
Product Planning, Sales Division, and Biomedical Division. Mr.
Milligan served as a Director of Pheromone from 2000-2006.

About Andrew Saxton
Mr. Saxton is currently Chairman of the King George Financial
Corporation and has had a long and successful career of leadership
roles in finance, commercial real estate and insurance. He is currently
a Director of Canadian Commercial Corporation (a Federal Crown
Corporation), Earthworks Industries Inc., Imperial Parking Canada
Corporation, and the University of British Columbia Investment
Management Trust. He was previously the co-founder and Executive Vice
President of Laurentide Financial Corporation, founder and President of
Elite Insurance and Chairman of Grouse Mountain Resorts Ltd. He has
been a Director with of several companies including BCTV, the
Commonwealth Bank of Nassau Bahamas, and the Insurance Corporation of
British Columbia, where he chaired the Investment Committee. He has
served on many advisory boards including the World Heart Federation,
the BC Life Sciences Fund and the Dean of Faculty of Medicine's
Community Advisory board at the University of British Columbia. From
2000-2006 Mr. Saxton was a director of Pheromone.

About Christopher Neuman
Mr. Neuman was a director of Pheromone from 2000 to 2006, serving as
its CEO until 2005. He has 35 years experience in the Canadian health
care industry, including positions as General Manager of ALZA Canada,
and President and General Manager of Baker Cummins Inc. He held senior
management positions with Marion Merrell Dow Inc., PharmaScience Inc.,
Boots Pharmaceuticals Ltd. and Neuromedical Systems Inc., where, as
General Manager, he was responsible for the establishment of a Canadian
subsidiary for the U.S. diagnostics company. His early career included
production & operations management, positions at Davis+Geck/Lederle
Laboratories, Elliot-Marion Co. Ltd., and sales and sales & marketing
management positions at Beecham Laboratories Inc.


Pheromone Sciences Corp. is a biotechnology research and development
company focused on commercializing medical technologies.



ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO


For further information contact:
Mr. Phil Morehouse
Pheromone Sciences Corp.
TEL: [phone]
FAX: [phone]

=======================================================================
Copyright (c) 2006 PHEROMONE SCIENCES CORP. (PHS) All rights reserved.
For more information visit our website at
http://www.pheromonesciences.com/ or send
mailto:[e-mail]
Message sent on Mon Jul 31, 2006 at 2:19:31 PM Pacific Time
=======================================================================

AntwortenAllen antwortenWeiterleitenUmleitenLöschen

[URANI]

Pheromone Builds Scientific Advisory Board: Sertoli Cell Expert
Dr. Jannette Dufour to Help Develop Diabetes Product=======================================================================

Kelowna, B.C. -- Pheromone Sciences Corp. ("Pheromone") is pleased to
announce that Dr. Jannette Dufour, PhD has joined its Scientific
Advisory Board ("SAB") to assist the company with its diabetes product
development.

"Because Sertoli cells are a key component of our project, Dr. Dufour's
extensive research into these cells significantly enhances our team,"
stated Dr. David White, Chair of Pheromone's SAB. "Her experience
working for the University of Alberta's Clinical Islet Transplant
Program [originators of the prominent 'Edmonton Protocol'] will be
particularly valuable."

Currently Assistant Professor in the Department of Cell Biology and
Biochemistry at Texas Tech University Health Sciences Center in Lubbock
Texas, Dr. Dufour's research was instrumental in developing the
technology leading to some of the Sertoli cell patents now licensed
exclusively to Pheromone. The Company owns the exclusive rights to over
20 patents related to the therapeutic use of Sertoli cells.

About Dr. Dufour
In 1999 Dr. Dufour received a PhD in Genetics and Cell Biology from
Washington State University, where she first began research on Sertoli
cells as a graduate student. She then went on to receive further
training as a postdoctoral fellow with Drs. Rajotte and Korbutt with
the Islet Transplantation Program at the University of Alberta. While
there she received five postdoctoral fellowships to study the use of
Sertoli cells as a way to immunoprotect transplanted islets. Dr.
Dufour is now an Assistant Professor at Texas Tech University Health
Sciences Center where she continues to investigate the immunoprotective
properties of Sertoli cells with the goal of developing ways to improve
the survival of transplanted islets.

Pheromone Sciences Corp. is a biotechnology research and development
company focused on commercializing medical technologies.


ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO

For further information contact:
Mr. Phil Morehouse
Pheromone Sciences Corp.
TEL: [phone]
FAX: [phone]

=======================================================================
Copyright (c) 2006 PHEROMONE SCIENCES CORP. (PHS) All rights reserved.
For more information visit our website at
http://www.pheromonesciences.com/ or send
mailto:[e-mail]
Message sent on Tue Aug 1, 2006 at 10:41:32 AM Pacific Time

[URANI]

Pheromone Sciences appoints Dufour to scientific board


2006-08-01 10:12 ET - News ReleaseMr. Dev Randhawa reports

PHEROMONE BUILDS SCIENTIFIC ADVISORY BOARD: SERTOLI CELL EXPERT DR. JANNETTE DUFOUR TO HELP DEVELOP DIABETES PRODUCT

Pheromone Sciences Corp. has appointed Dr. Jannette Dufour, PhD, to its scientific advisory board to assist the company with its diabetes product development.

"Because Sertoli cells are a key component of our project, Dr. Dufour's extensive research into these cells significantly enhances our team," stated Dr. David White, chair of Pheromone's SAB. "Her experience working for the University of Alberta's clinical islet transplant program (originators of the prominent Edmonton protocol) will be particularly valuable."

Currently assistant professor in the department of cell biology and biochemistry at Texas Tech University Health Sciences Center in Lubbock, Tex., Dr. Dufour's research was instrumental in developing the technology leading to some of the Sertoli cell patents now licensed exclusively to Pheromone. The company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

About Dr. Dufour

In 1999, Dr. Dufour received a PhD in genetics and cell biology from Washington State University, where she first began research on Sertoli cells as a graduate student. She then went on to receive further training as a postdoctoral fellow with Dr. Rajotte and Dr. Korbutt with the Islet transplantation program at the University of Alberta. While there, she received five postdoctoral fellowships to study the use of Sertoli cells as a way to immunoprotect transplanted islets. Dr. Dufour is now an assistant professor at Texas Tech University Health Sciences Center, where she continues to investigate the immunoprotective properties of Sertoli cells with the goal of developing ways to improve the survival of transplanted islets.

[URANI]

Na wer hat sich da heute wieder eingedeckt




Time Ex Price Change Volume Buyer Seller Markers

12:08:38 V 0.42 -0.02 1,000 7 TD Sec 33 Canaccord K

11:55:24 V 0.43 -0.01 150,000 33 Canaccord 33 Canaccord K

11:18:05 V 0.43 -0.01 5,500 7 TD Sec 46 Blackmont K

10:53:54 V 0.43 -0.01 2,000 7 TD Sec 7 TD Sec K

10:03:34 V 0.44 - 16,500 14 ITG 46 Blackmont K

10:02:01 V 0.44 - 8,500 14 ITG 7 TD Sec KL

[URANI]

Pheromone Sciences - Dr. White audio announcement
=======================================================================

Dear Investors,

We thought you might be interested in an online interview recently
completed by Dr. David White: Chairman of the company's Scientific
Advisory Board and Professor of Xenotransplantation at the University
of Western Ontario.

In the interview Dr. White discusses the primary causes and effects of
diabetes as well as the work being done by Pheromone Sciences Corp.
through Xenotransplantation to restore those affected by diabetes back
to health.

Click here to listen to the interview.

https://www.transworldnews.com/Interviews.aspx?id=31

=======================================================================
Copyright (c) 2006 PHEROMONE SCIENCES CORP. (PHS) All rights reserved.
For more information visit our website at
http://www.pheromonesciences.com/ or send
mailto:[e-mail]
Message sent on Wed Aug 2, 2006 at 4:37:45 PM Pacific Time
=======================================================================

[URANI]

Pheromone Sciences: CTV News story=======================================================================

Greetings,

Below you will find the link to a recent TV news story related to the
diabetes treatment conducted by Dr. Rafael Valdes in Mexico City.
Click on the link under the "Video" title on the right-hand side of the
webpage to view the 2 minute clip.

Please note that Pheromone Sciences is not affiliated with Dr. Valdes.
However we are conducting the necessary preclinical experiments to
verify this method of treating Type 1 diabetes, as required by the
USFDA and Health Canada to approve the technology for human use. We
own the exclusive rights to over 20 patents for the therapeutic use of
Sertoli cells which is a key ingredient in the transplants.

http://snipurl.com/wd7w

If you have any questions about this story or the Pheromone research
project, please give me a call at the number below. Also be sure to
check out an audio interview with our principal researcher Dr. David
White on the homepage of our website at www.pheromonesciences.com.

Regards,

Phil Morehouse
Pheromone Sciences Corp.
#810 -- 1708 Dolphin Ave.
Kelowna, BC V1Y 9S4
Canada

Ph: 250-868-8177
Fax: [phone]
TF: 888-318-7062
[e-mail]

=======================================================================
Copyright (c) 2006 PHEROMONE SCIENCES CORP. (PHS) All rights reserved.
For more information visit our website at
http://www.pheromonesciences.com/ or send
mailto:[e-mail]
Message sent on Wed Sep 13, 2006 at 12:36:50 PM Pacific Time
=======================================================================

[URANI]

Re: News Release - Wednesday, September 20, 2006
Diabetic Product Development Leads to Name Change: Sernova Corp.
=======================================================================

Kelowna, B.C. - Pheromone Sciences Corp. is pleased to announce it has
changed its name to Sernova Corp. ("Sernova"). The company's new stock
symbol is SVA.

"The new name fits better with projects such as our current development
of a potential breakthrough treatment for diabetes," said Chairman Dr.
William Cochrane. "We wanted a new name to help make it clear to
investors that our focus is no longer centred around pheromones, but
can include all kinds of biotechnology developments."

Shareholders approved the name change at the Company's annual general
meeting held on August 18th 2006 and elected 5 directors to the Board:
Dr. William Cochrane (Chair), Charles Allard, Justin Leushner, Devinder
Randhawa and Dr. Eldon Smith.

The Company's officers are: Chief Executive Officer-Devinder Randhawa,
President-Justin Leushner, and Chief Financial Officer and Corporate
Secretary-Patrick Groening.

Sernova Corp. is a biotechnology research and development company
focused on commercializing medical technologies.

This news release may contain forward-looking statements.
Forward-looking statements address future events and conditions and
therefore involve inherent risks and uncertainties. Actual results may
differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO

For further information contact:
TEL: [phone] Mr. Phil Morehouse
FAX: [phone] Sernova Corp.

=======================================================================
Copyright (c) 2006 PHEROMONE SCIENCES CORP. (PHS) All rights reserved.
For more information visit our website at
http://www.pheromonesciences.com/ or send
mailto:[e-mail]
Message sent on Wed Sep 20, 2006 at 8:34:05 AM Pacific Time
=======================================================================

[URANI]

Na da wird aber ordentlich eingekauft im September..



Pheromone Sciences Corp. (PHS) As of September 19th, 2006
Filing Date Transaction Date Insider Name Nature of transaction Securities # or value acquired or disposed of Unit Price
Sep 18/06 Sep 12/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 50,000 $0.400
Sep 18/06 Sep 12/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 50,000 $0.400
Sep 18/06 Sep 11/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 50,000 $0.420
Sep 14/06 Sep 08/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 100,000 $0.420
Sep 14/06 Apr 15/06 Milligan, William Doran 50 - Grant of options Options 95,000 $0.400
Sep 11/06 Jul 10/06 Allard, Charles Richard 00 - Opening Balance-Initial SEDI Report Options
Sep 07/06 Aug 30/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 12,000 $0.430
Sep 07/06 Aug 30/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 14,000 $0.420
Sep 07/06 Aug 30/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 5,000 $0.430
Sep 07/06 Aug 30/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 4,000 $0.420

[URANI]

=======================================================================
Re: News Release - Monday, September 25, 2006
Dr. George Adams Appointed to Board of Directors to Help
Commercialize Insulin Dependent Diabetes Product
=======================================================================

Kelowna, B.C. -- Sernova Corp. ("Sernova") is pleased to announce that
Dr. George Adams of Toronto, Ontario has been appointed to the Board of
Directors to assist Sernova in moving its diabetes product development
to the commercialization stage.

"Dr. Adams' success as both a scientist and an entrepreneur makes him
an ideal fit for our board." said Sernova's Chairman Dr. William
Cochrane. "His extensive experience in financing start-ups and
effectively commercializing medical research will be very helpful."

Dr. Adams has been a founding angel investor in six start-up companies
in Canada and the United States and was instrumental in obtaining
venture financing for 24 companies who have raised a total of $85
million. He has also been a Director of 10 venture capital funds and 8
start-up companies.

Dr. Adams has published his work in 124 publications including 9
invited reviews, 26 full papers and 3 patents. He is a past President
of the Canadian Biomaterials Society. He has been a reviewer for
numerous scientific journals, national granting agencies and several
national and provincial centres of excellence. He has been a principal
investigator for over $40 million in private and publicly-funded
research and development.

About Dr. George Adams
Dr Adams obtained his Ph.D. in Medical Sciences from McMaster
University after completing his B.A.Sc. and M.A.Sc. in Mechanical
Engineering at the University of Waterloo. After a postdoctoral year at
the Baylor College of Medicine studying vascular biology, he became a
Senior Scientist in the Canadian Red Cross Blood Transfusion Service.
He then accepted a position with the University of Ottawa as the
Director of its Artificial Heart Development Program and an Associate
Professor of Biochemistry and Surgery.

Dr. Adams left his position at the University of Ottawa to start his
own company and developed a diagnostic product, which were subsequently
commercialized by DuPont Canada Inc. In 1994 he became the controlling
shareholder and President of Corvita Canada and financed its research
program until the company was purchased by Pfizer in 1996 and later
re-sold to Boston Scientific in 1998. From 1999 through 2004, Dr. Adams
was Chief Executive Officer of the University of Toronto Innovations
Foundation. Since 2005, he has served as the Chief Executive Officer
and a Director of Amorfix Life Sciences Ltd.

About Sernova
Sernova Corp. is a Canadian based, biotechnology research and
development company focused on commercializing medical technologies.
Current emphasis is to successfully commercialize a potential
breakthrough product for insulin dependent diabetes. According to the
American Diabetes Association approximately 9 million Americans require
insulin injections and it is the sixth leading cause of death in the
United States. Over $100 billion per year is spent in the US on
treating diabetes and its complications.

This news release may contain forward-looking statements.
Forward-looking statements address future events and conditions and
therefore involve inherent risks and uncertainties. Actual results may
differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD
"Dev Randhawa"
Dev Randhawa, CEO

For further information contact:
Mr. Phil Morehouse
Sernova Corp.
TEL: [phone]
FAX: [phone]

=======================================================================
Copyright (c) 2006 PHEROMONE SCIENCES CORP. (PHS) All rights reserved.
For more information visit our website at
http://www.pheromonesciences.com/ or send
mailto:[e-mail]
Message sent on Mon Sep 25, 2006 at 1:54:51 PM Pacific Time
====================================================================

[URANI]

Pheromone Sciences changes name to Sernova


2006-09-19 16:46 ET - Change Name

Also New Listing (C-SVA) Sernova Corp

The company has changed its name as follows. There is no consolidation of capital.

Effective at the opening Sept. 20, 2006, the common shares of Sernova Corp. will commence trading on the TSX Venture Exchange and the common shares of Pheromone Sciences Corp. will be delisted. The company is classified as a research and development in the life sciences company.

[URANI]

Pheromone grants two million options to insiders


2006-09-12 14:48 ET - Options ProposedMr. Dev Randhawa reports

PHEROMONE GRANTS STOCK OPTIONS

Pheromone Sciences Corp. is granting incentive stock options to directors, officers, consultants and employees to purchase up to two million common shares at 40 cents per share for a period of five years expiring Sept. 11, 2011. The options will be fully vested over three years.

[URANI]

Und das kaufen geht weiter..........


Sernova Corp. (SVA) As of October 4th, 2006
Filing Date Transaction Date Insider Name Nature of transaction Securities # or value acquired or disposed of Unit Price
Oct 04/06 Oct 03/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 30,000 $0.330
Oct 03/06 Oct 02/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 2,500 $0.335
Oct 03/06 Sep 28/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 47,500 $0.335
Oct 02/06 Sep 25/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 25,000 $0.420
Sep 27/06 Sep 20/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 25,000 $0.415
Sep 27/06 Sep 19/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 25,000 $0.370
Sep 27/06 Sep 19/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 6,000 $0.375
Sep 27/06 Sep 19/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 30,000 $0.380
Sep 27/06 Sep 19/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 14,000 $0.375
Sep 27/06 Sep 19/06 Randhawa, Devinder 10 - Acquisition in the public market Common Shares 25,000 $0.380

[URANI]

Neuer Name: SERNOVA CORP. TSX:SVA

http://www.sernovacorp.com